A securities class action has been filed against Phreesia, Inc. (PHR) on behalf of all investors who purchased or otherwise acquired Phreesia common stock between May 8, 2025 through March 30, 2026. This case has been filed in the USDC – DE.
On March 30, 2026, Phreesia announced its financial results for the fourth quarter and fiscal year ended January 31, 2026 and reduced its revenue guidance for fiscal year 2027. The Company attributed the reduction to weakness in pharmaceutical marketing and poor visibility in its Networking Solutions segment.
On this news, Phreesia’s stock price fell $3.03 per share, or 26.56%, to close at $8.38 per share on March 31, 2026.
The complaint alleges taht During the Class Period, Defendants made materially false and misleading statements and engaged in a scheme to deceive the market and a course of conduct that artificially inflated the price of Phreesia’s common stock and operated as a fraud or deceit on Class Period purchasers of Phreesia’s common stock by materially misleading the investing public. Later, Defendants’ prior misrepresentations and fraudulent conduct became apparent to the market, the price of Phreesia’s common stock materially declined, as the prior artificial inflation came out of the price over time.